UPDATE: Prothena Corp. (PRTA) Reports Q1 EPS Loss of $1.26

May 8, 2018 4:35 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - May 8, 2018 4:36 PM EDT)

Prothena Corp. (NASDAQ: PRTA) reported Q1 EPS of ($1.26), $0.73 worse than the analyst estimate.

  • Net cash used in operating and investing activities was $31.8 million in the first quarter; quarter-end cash and restricted cash position of $433.1 million supports advancement through key milestones of R&D pipeline
  • Entered into global neuroscience research & development collaboration with Celgene to advance novel therapies for patients with neurodegenerative diseases
  • Initiated a first-in-human study of PRX004 in patients with ATTR amyloidosis

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities